Navigation Links
Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
Date:3/20/2009

PHILADELPHIA, Pennsylvania and DUBLIN, Ireland, March 20 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) announces that it has filed a lawsuit in the U.S. District Court of the Southern District of New York against Mylan Inc., Mylan Pharmaceuticals Inc. and Matrix Laboratories Limited (collectively "Mylan") for infringement of Shire's patent: U.S. Patent No. 5,968,976 ("'976 Patent").

The lawsuit was filed in response to an Abbreviated New Drug Application ("ANDA") filed by Mylan seeking FDA approval to market and sell generic versions of Shire's 500 mg, 750 mg, and 1 g FOSRENOL(R) (lanthanum carbonate) products.

Under the Hatch-Waxman Act, because Shire filed its patent infringement lawsuit within 45 days of receiving Mylan's Paragraph IV notification letter, the FDA must refrain from approving Mylan's ANDA for 30 months, or until a District Court decision finding that the patent is invalid or not infringed, whichever occurs earlier. The stay on generic approval will expire on April 26, 2012 unless terminated earlier.

Shire has asserted the '976 patent based upon information provided to it by Mylan. Shire will continue to evaluate the situation throughout the litigation and will take all necessary actions to protect its rights to the fullest extent possible. Shire has a robust patent estate and is confident that it will protect the FOSRENOL franchise.

Shire PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
2. Shire Announces Opening of Office in Japan
3. Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
4. Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion
5. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
6. Shire plc: Change to Directors Details
7. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
8. Shires New Product Portfolio Delivers Strong Quarterly Performance
9. Change of Name to Shire plc
10. Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document
11. Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Product and ... very low abundance and are often “lost in ... time-consuming. , Join presenters Dr. Rowel Tobias, Senior ... John Anders, Head of Quality at Nanotherapeutics, Inc., ... that can speed detection and quantitation while achieving ...
(Date:7/10/2014)... Understanding the need for better quality and higher ... that currently exists in this area, ChanTest has recently ... validated ion channel and GPCR cell lines. ChanTest’s ... channels control many critical physiological functions throughout the body. ... to treat a variety of human diseases. , ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Unraveling ... closer together. The Archer Family purchased a ... within DNA, but ended up with a lifetime of ... contained within the family members’ DNA genuinely brought the ... decided to search deeper into genetic history and prior ...
(Date:7/10/2014)... 10, 2014 OMICS Group’s 5th International ... 18-20 August, 2014 at Double Tree by Hilton Beijing, ... developments in Analytical & Bioanalytical research methods only to ... on this occasion, Dr. Srinubabu Gedela, MD of OMICS ... is a remarkable one in bringing a unique and ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, ... and bioimplants processed from human amniotic membrane, announced ... Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders ... Petit, Chairman and CEO, William C. Taylor, President ...
... and TORONTO, Dec. 1, 2011 Generex Biotechnology Corporation ... on the status of the clinical and regulatory ... insulin spray product. Work has been ... analyses), and revising all of the extant Generex ...
... Calif., Dec. 1, 2011  VIVUS, Inc. (NASDAQ: VVUS ... present an overview of the company at the 2011 Deutsche ... place at the Four Seasons Hotel, Boston, MA on Tuesday, ... and 30-day archive of the presentation will be available at ...
Cached Biology Technology:Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program 2Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program 3Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program 4VIVUS to Present at the Deutsche Bank BioFEST Conference 2VIVUS to Present at the Deutsche Bank BioFEST Conference 3
(Date:7/11/2014)... German . ... refraction of X-rays through a specimen instead of attenuation ... are often of much higher quality than those based ... Franz Pfeiffer are particularly interested in developing new approaches ... phase-contrast imaging. One main goal is to make this ...
(Date:7/11/2014)... National Institute of Standards and Technology (NIST) need ... effectively, they often prove that necessity is truly ... recently for M. Lorna De Leoz and Stephen ... of glycomics. Glycomics is the study of the ... attached to proteins and lipids and influence cellular ...
(Date:7/11/2014)... China Researchers from Salk Institute for Biological Studies, ... evaluated the safety and reliability of the existing ... new method, TALEN-HDAdV, which could significantly increased gene-correction ... This study published online in Cell Stell ... stem cell-based gene therapy. , The combination of ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2A new genome editing method brings the possibility of gene therapies closer to reality 2
... target for a drug seems very promising on paper; ... of telomerase inhibitors,to treat cancer; they are supposed to ... cells. Yet, something in the cell,seems to block their ... do then? Scrap the project? Look for something,else? Hell ...
... in humans in forests between Gabon and the Republic ... animal carcasses, according to a study by the Wildlife ... the February edition of the journal Emerging Infectious Diseases, ... Ebola between 2001 and 2003 produced positive results, and ...
... by human activity and the extinction of species around ... warns a Canadian zoologist. This ecological damage also endangers ... , Dr. Daniel (Dan) Brooks, a parasitologist at the ... is linked to the emergence of new human and ...
Cached Biology News:Combination therapy boosts effectiveness of telomere-directed cancer cell death 2Study Links Ebola Outbreaks To Animal Carcasses 2Ecological destruction fuels emerging diseases 2
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
...
... genetically encoded fluorescent sensor capable for high ... one of the main ROS generated by ... fluorescent protein inserted into the regulatory domain ... demonstrates submicromolar affinity to H2O2 and at ...
Alexa Fluor 647 anti-mouse Qa-2...
Biology Products: